Universal Early Parenting Programmes: Unraveling the Cost-Effectiveness

By Thanusha Pillay

June 14, 2024

Introduction

Inadequate care during infancy can have lasting repercussions, impacting various sectors and necessitating increased expenditure on health, social, educational, and judicial services. Positive parenting is a growing public health priority and parenting programmes have been shown to be valuable and effective. Universal Early Parenting Programmes are increasingly popular for enhancing positive parenting practices and addressing skill and attitude gaps across diverse populations.

The Efficacy of Universal Parenting Interventions

Research underscores the potential of early parenting programmes in enhancing parental knowledge and skills. While short-term benefits are evident, long-term impacts of universal interventions on parenting and child development are not thoroughly investigated.

Exploring the Parent and Infant Programme

This study looked into the cost and cost-effectiveness of the Parent and Infant (PIN) programme, a universal intervention targeting parental attitudes and responsive parenting strategies during the early years. The researchers piloted the program in two sites in the Republic of Ireland and compared it to services as usual (SAU). They assessed the cost-effectiveness of the program from an Irish health and social care perspective over 24 months. The primary outcome measure was the Parenting Sense of Competence Scale (PSOC), and by focusing on parent satisfaction this analysis sheds light on the programme’s efficacy.

Fig. 1

Figure 1. Overview of the PIN programme adapted from Hickey et al., 2020

Results and Cost Analysis

With 163 parent-infant dyads analysed (86 in the programme, 77 control), the PIN programme demonstrated a mean cost of €647 per dyad. The PIN service achieved a mean incremental cost-effectiveness of €614 per PSOC unit gained. At a willingness-to-pay of €1,000 per one unit change in the PSOC, the PIN programme proved cost-effective compared to SAU. The PIN programme showcased positive impacts on parental competence and was viable at a reasonable threshold.

Discussion and Implications

While the study highlights the success of the PIN programme, challenges in evaluating the cost-effectiveness of early interventions persist. The complexities of assessing outcomes in children, coupled with the need for a broader evaluative framework, highlight the necessity for further research and nuanced approaches to appraise the effectiveness of such programmes.

Conclusion

The study emphasise the potential of Universal Early Parenting Programmes in enhancing parental competence and fostering positive childhood behavioural outcomes. Navigating cost-effectiveness challenges, the field requires more research and robust trials to inform policy decisions and resource allocation effectively.

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.